Literature DB >> 22871754

Patient-reported outcomes in idiopathic pulmonary fibrosis research.

Jeffrey J Swigris1, Diane Fairclough2.   

Abstract

Patient-reported outcomes (PROs) include questionnaires or surveys that ask patients for their perceptions about things like symptoms they are experiencing or quality of life. For incurable, morbid, life-shortening conditions like idiopathic pulmonary fibrosis (IPF), PROs are particularly germane: They elucidate for clinicians and researchers what it is like for patients to live with such a disease, and they may detect important treatment effects not captured by other metrics (eg, pulmonary physiology). However, a relative paucity of research on PROs in IPF has left significant knowledge gaps in this area and contributed to the timidity investigators have about using PROs as prominent outcomes in IPF drug trials. Additional research on existing instruments is needed to establish or bolster their basic psychometric properties in IPF. When PROs are used as end points in therapeutic trials, analyzing PRO response data can be challenging, but these challenges can be overcome with a transparent, thoughtful, and sophisticated statistical approach. In this article, we discuss some of the basics of PRO assessment, existing knowledge gaps in IPF-related PRO research, and the potential usefulness of using PROs in IPF trials and conclude by offering specific recommendations for an approach to analyzing repeated-measures PRO data from IPF trials.

Entities:  

Mesh:

Year:  2012        PMID: 22871754      PMCID: PMC3425334          DOI: 10.1378/chest.11-2602

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  23 in total

1.  Measurement of health outcomes in treatment effectiveness evaluations: conceptual and methodological challenges.

Authors:  D L Patrick; Y P Chiang
Journal:  Med Care       Date:  2000-09       Impact factor: 2.983

2.  Responsiveness to change: an aspect of validity, not a separate dimension.

Authors:  R D Hays; D Hadorn
Journal:  Qual Life Res       Date:  1992-02       Impact factor: 4.147

3.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

Authors:  Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Ganesh Raghu; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2011-08-15       Impact factor: 21.405

Review 4.  Health-related quality of life among patients with idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Michael K Gould; Sandra R Wilson
Journal:  Chest       Date:  2005-01       Impact factor: 9.410

5.  A critical appraisal of the quality of quality-of-life measurements.

Authors:  T M Gill; A R Feinstein
Journal:  JAMA       Date:  1994 Aug 24-31       Impact factor: 56.272

Review 6.  Missing quality of life data in cancer clinical trials: serious problems and challenges.

Authors:  J Bernhard; D F Cella; A S Coates; L Fallowfield; P A Ganz; C M Moinpour; P Mosconi; D Osoba; J Simes; C Hürny
Journal:  Stat Med       Date:  1998 Mar 15-Apr 15       Impact factor: 2.373

7.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Kevin K Brown; Ganesh Raghu; Roland M du Bois; David A Lynch; Fernando Martinez; Dominique Valeyre; Isabelle Leconte; Adele Morganti; Sébastien Roux; Juergen Behr
Journal:  Am J Respir Crit Care Med       Date:  2011-04-07       Impact factor: 21.405

8.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin K Brown; Williamson Z Bradford; Karen Starko; Paul W Noble; David A Schwartz; Talmadge E King
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

9.  Pulmonary lesions in childhood onset systemic lupus erythematosus: analysis of 26 cases, and summary of literature.

Authors:  R L Nadorra; B H Landing
Journal:  Pediatr Pathol       Date:  1987

Review 10.  Recommendations on health-related quality of life research to support labeling and promotional claims in the United States.

Authors:  D A Revicki; D Osoba; D Fairclough; I Barofsky; R Berzon; N K Leidy; M Rothman
Journal:  Qual Life Res       Date:  2000       Impact factor: 3.440

View more
  14 in total

1.  Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Authors:  Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo
Journal:  Curr Respir Med Rev       Date:  2015

2.  The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia.

Authors:  E Haydn Walters; Andrew J Palmer; Ingrid A Cox; Barbara de Graaff; Hasnat Ahmed; Julie Campbell; Petr Otahal; Tamera J Corte; Ian Glaspole; Yuben Moodley; Nicole Goh; Sacha Macansh
Journal:  Qual Life Res       Date:  2021-05-17       Impact factor: 4.147

3.  Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.

Authors:  Timothy S Blackwell; Andrew M Tager; Zea Borok; Bethany B Moore; David A Schwartz; Kevin J Anstrom; Ziv Bar-Joseph; Peter Bitterman; Michael R Blackburn; William Bradford; Kevin K Brown; Harold A Chapman; Harold R Collard; Gregory P Cosgrove; Robin Deterding; Ramona Doyle; Kevin R Flaherty; Christine Kim Garcia; James S Hagood; Craig A Henke; Erica Herzog; Cory M Hogaboam; Jeffrey C Horowitz; Talmadge E King; James E Loyd; William E Lawson; Clay B Marsh; Paul W Noble; Imre Noth; Dean Sheppard; Julie Olsson; Luis A Ortiz; Thomas G O'Riordan; Tim D Oury; Ganesh Raghu; Jesse Roman; Patricia J Sime; Thomas H Sisson; Daniel Tschumperlin; Shelia M Violette; Timothy E Weaver; Rebecca G Wells; Eric S White; Naftali Kaminski; Fernando J Martinez; Thomas A Wynn; Victor J Thannickal; Jerry P Eu
Journal:  Am J Respir Crit Care Med       Date:  2014-01-15       Impact factor: 21.405

4.  The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.

Authors:  Surinder S Birring; Donald M Bushnell; Michael Baldwin; Heiko Mueller; Natalia Male; Klaus B Rohr; Yoshikazu Inoue
Journal:  Eur Respir J       Date:  2022-06-02       Impact factor: 33.795

5.  Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.

Authors:  Marlies S Wijsenbeek; Jan C Grutters; Wim A Wuyts
Journal:  Adv Ther       Date:  2015-07-15       Impact factor: 3.845

Review 6.  IPF clinical trial design and endpoints.

Authors:  Steven D Nathan; Keith C Meyer
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

Review 7.  Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?

Authors:  Steven D Nathan; Christopher S King
Journal:  Drug Des Devel Ther       Date:  2014-07-02       Impact factor: 4.162

Review 8.  The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review.

Authors:  Jeffrey J Swigris; Dirk Esser; Craig S Conoscenti; Kevin K Brown
Journal:  Health Qual Life Outcomes       Date:  2014-08-20       Impact factor: 3.186

9.  Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry.

Authors:  Emily C O'Brien; Michael T Durheim; Victoria Gamerman; Sandy Garfinkel; Kevin J Anstrom; Scott M Palmer; Craig S Conoscenti
Journal:  BMJ Open Respir Res       Date:  2016-01-11

Review 10.  Minimal clinically important difference in idiopathic pulmonary fibrosis.

Authors:  Mohleen Kang; Lucian Marts; Jordan A Kempker; Srihari Veeraraghavan
Journal:  Breathe (Sheff)       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.